Navigation Links
Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board
Date:3/27/2013

NEW YORK, March 27, 2013 /PRNewswire/ -- Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced it has appointed an Advisory Board comprising renowned industry experts and visionaries in digital pathology. As part of its market expansion strategy, Definiens established the new Board to provide independent advice on trends and opportunities in tissue diagnostics and clinical digital pathology. Members of the Advisory Board include: - Ron A. Andrews , President, Medical Sciences, Life Technologies and former CEO of Clarient and CEO of GE Molecular Diagnostics - Prof. Uwe Bicker , Dean of the Medical Faculty Mannheim, University of Heidelberg and a member of the board of directors of Sanofi SA - Prof. Manfred Dietel , Director, Institute of Pathology, Charite Berlin and chairman of the German Society for Pathology - Eric F. Glassy, M.D., Medical Director, Pathology, Inc. and chairman of the Digital Pathology Working Group of the College of American Pathologists - Prof. Gerd Binnig , Founder and CTO, Definiens (Moderator). "Definiens is working to advance personalized medicine by contributing to the development of next generation diagnostics, and bringing those novel diagnostics into clinical practice. Our innovations have the potential to transform daily clinical practice for the benefit of both patients and pathologists, particularly in oncology," said Thomas Heydler , CEO of Definiens. "We will greatly benefit from the wealth of experience of the Advisory Board members while expanding our business into tissue diagnostics and clinical digital pathology." As part of its goal to guide Definiens during the company's expansion, the Advisory Board will discuss trends in digital pathology and highlight opportunities for image and data analysis to revolutionize clinical practice in pathology. Specific topics of discussion will include pathology workflow, tissue diagnostic test development, personalized medicine and next-generation cancer treatment, as well as future technology and market requirements. Definiens founder and Nobel laureate, Professor Gerd Binnig , will catalyze the discussions. "With the novel opportunities enabled by digital pathology, progress in diagnosing and treating cancer will be accelerated. The visionary power and expertise brought together in the Definiens Advisory Board will be invaluable on our path towards bringing advanced image analysis to clinical pathology," said Prof. Gerd Binnig , Founder and CTO of Definiens. About Definiens Definiens is the leading provider of image analysis and data mining solutions for life sciences, tissue diagnostics and clinical digital pathology. Definiens software provides detailed cell-by-cell readouts from target structures on whole tissue slides, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens' vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients' lives. Definiens is headquartered in Munich, Germany and has offices throughout the United States. Further information is available at www.definiens.com. Media Contact Definiens AG Dr Florian Leiss Manager Marketing Communications +49 (89) 2311-8024 fleiss@definiens.com About Gilde Healthcare Partners Gilde Healthcare Partners (Utrecht, The Netherlands and Cambridge, USA) is a transatlantic venture and growth capital firm focused on private healthcare technology and service companies. It has over €450 million ($600 million) under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €15 million ($20 million) in a single portfolio company. For a list of Gilde's portfolio companies please visit the website at www.gildehealthcare.com.

Media Contact: Dr Florian  Leiss , +49 (89) 2311-8024, fleiss@definiens.com


'/>"/>
SOURCE Gilde Healthcare Partners
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
2. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
3. Boston Healthcare Associates Roundtable Explores Challenges and Opportunities Surrounding the Value of Big Data within the Life Sciences
4. Bioethics for Beginners: 60 Cases and Cautions from the Moral Frontier of Healthcare
5. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
6. Premier Healthcare Renews Supplier Agreement with Masimo
7. BGI, GE Healthcare team up on pioneering stem cell science projects
8. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
9. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
10. BUSM/VA Boston Healthcare System investigators identify new gene linked to PTSD
11. Mount Sinai grad student, 25, named to Forbes 30 Under 30 in Science and Healthcare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... -- The Department of Transport Management (DOTM) of ... US Dollar project, for the , Supply and ... and IT Infrastructure , to Decatur ... of Identity Management Solutions. Numerous renowned international vendors participated in ... was selected for the most compliant and innovative solution. ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology: